

Exhibit 99.1
Alcon, Inc.
Slides used during the Alcon, Inc. AAO Presentation
November 7, 2008



**Alcon Investor
Meeting at AAO**

November 7, 2008

Alcon

Safe Harbor Statement

This presentation, made on November 7, 2008, includes forward-looking statements based on current expectations and Alcon does not undertake the obligation to update the forward-looking information or statements. These expectations could differ materially from actual results and are subject to a number of uncertainties and risks as detailed in the company's form 20-F filed with the SEC on March 18, 2008.

In addition, this presentation may include several financial measures, to assist in better understanding our business, that are not prepared in accordance with generally accepted accounting principles (GAAP). These non-GAAP financial measures will be reconciled at the end of this presentation or in associated public information filed with the SEC.

Reports noted above are available on our website at www.alcon.com in the "Investors and Media" section. For further information contact the Alcon Investor Relations Department at (817) 551-8805.

Alcon[®]

Agenda

Topic	Speaker
Opening Remarks	Cary Rayment
Product Growth Drivers	Kevin Buehler
Question & Answer Session	Cary Rayment Rick Groarkin Kevin Buehler Sabri Markabi, PhD

Alcon

Long Term Favorable Business Model

- Diversified business model with multiple sources for growth
 - Global reach and leadership unmatched
- Solid long term fundamentals underlie our markets and our business
- New products in pipeline at all stages of development
- Long history of solid execution and financial performance
- Long term business model of 8-10% organic sales growth and positive margin evolution remains intact

Alcon[®]

Alcon in the Current Market Environment

- **Clear appreciation for current economic environment and potential impact on markets and our business**
- **Expect to deliver lower end of long term organic growth range in 2009**
 - Economic Impacts and TobraDex®
- **Facing currency headwind of 5-6% in 2009 (at current rates)**
- **Commercial operations expansion largely complete for now**
 - Expect P&L leverage from investment in infrastructure
 - Making business decisions to deliver margin improvement
- **Reviewing investment portfolio**
- **Expanding investment in research and in-licensing**
 - Focusing on Glaucoma, Retina and Dry Eye

Alcon®

Research and Development Projects

Glaucoma

- **AZARGA®** a new glaucoma combination ex-US (Approval Pending)
- **Travatan® Z** clinical differentiation (Phase IV)
- **Aneceortave Acetate** for Glaucoma studies and represents a shift in patient compliance (Phase II)

Retina

- **RTKi** compound for wet AMD (Phase II)
- **Tandisplirone** for dry AMD (Phase I)

Cataract

- **ReSTOR® Aspheric +3.0 IOL** in U.S. (PMA filed in Q2 2008)
- **AcrySof® Toric** higher power lenses (Advanced development)
- **AcrySof® Phakic IOL** (CE Marked in EU, Advanced Development in U.S)
- **AcrySof® ReSTOR® Aspheric Toric IOL** (Early Development)

Alcon

Product Growth Drivers

Advanced Technology
IOLs

New Equipment
Platforms

New Glaucoma
Formulations

Alcon[®]

Product Growth Drivers

Advanced Technology
IOLs

New Equipment
Platforms


New Glaucoma
Formulations

Alcon[®]

Alcon Remains the #1 Choice in PC-IOLs


PC-IOL Usage Share as a % of Surgeons

4Q 2007



■ ReSTOR/ReSTOR Aspheric
■ ReZoom+
■ Crystallens+

3Q 2008



■ ReSTOR/ReSTOR Aspheric
■ ReZoom+
■ Crystallens+
■ Crystallens HD+

*Trademarks are property of their respective owners.

Source: Alcon Internal Data

Alcon

AcrySof® ReSTOR® +3.0 Key Benefits



AcrySof® ReSTOR® +3.0

- Received CE mark in Q3 2007
- Announced ex-U.S. launch at ESCRS in September
- Filed PMA with FDA in Q2 2008, expecting response by early 2009

- Aspheric acrylic design based on highly biocompatible AcrySof® Materials
- Maintains all visual performance benefits of +4.0 at near, intermediate and distance
- Extends reading distance by 7cm (2.8 in)
- Improves intermediate visual acuity by 1 – 1.5 line(s)
- Aspheric optic provides improved image quality
- Higher rate of patient satisfaction and spectacle independence

Alcon

Visual Acuity Comparison of the ReSTOR® Lenses

Improved Vision at All Distances

	ReSTOR® Aspheric +3.0	ReSTOR® Aspheric +4.0
20/20 or Better	31.2%	8.4%
20/25 or Better	81.8%	21.4%
20/32 or Better	86.2%	49.6%
20/40 or Better	94.9%	71.8%
Worse than 20/40	5.1%	28.2%

Note: Comparison of ACRYSOFT® ReSTOR® Aspheric 3 months postoperatively after binocular implantation.

Data on file. Alcon, Inc.

Alcon

Mean Visual Disturbances



ACRI.LISA[®]




REZOOM[®]



TECNIS[®]




ReSTOR[®] Aspheric +4.0



ReSTOR[®] Aspheric +3.0

*Trademarks are property of their respective owners.

Images provided by Jim Schwiegerling at the University of Arizona.



AcrySof® Toric Distinguishing Characteristics



AcrySof® Toric

Precise astigmatic correction

Unparalleled rotational stability

Distance vision and spectacle freedom

Calculator for precise surgical planning

Member of the proven AcrySof® platform

Diopter extensions are in development

Alcon®

Near Full Penetration of AcrySof® Toric

Penetration Rate Among Toric Implanting Surgeons



U.S. Unit Market Share for Toric Lenses as of Q2 2008



Alcon

AcrySof® Phakic Lens Attributes

Unique design and
biocompatible material

Low haptic force and vault
dynamic response

Small incision delivery with
minimal endothelial cell loss

Effective visual correction
supported by clinical results

Refractive power range of
-6.0 to -16.5

Potential expansion to toric
and presbyopic correction




AcrySof® Phakic
(Currently not available in the U.S.)

Alcon

AcrySof® Phakic Lens Effects on Visual Acuity

Change in Best Spectacle Corrected Visual Acuity from Pre-Operation

Over 50% of patients achieved one line or more increase over pre-op at both 1 and 3 years



US Status: Investigational device limited by Federal Law to investigational use only.

Data on file. Alcon, Inc.

AcrySof® Phakic: Effects on Endothelial Cells

Mean Chronic Loss in Central ECD

Minimal effect on Chronic Endothelial Cell Density (ECD) with year 1 and 2 show gains in ECD



Data shown is mean change with upper 90% confidence interval.

US Status: Investigational device limited by Federal Law to investigational use only.

Data on File. Alcon, Inc.

Alcon

Alcon at the AAO: IOLs

- **SOE: Astigmatism Correction with Alcon Toric IOLs**
 - Sunday, 11/9, 2:00-3:30 p.m., Georgia World Congress Center, Level 1, Hall B-5

- **Common Pitfalls of Presbyopia-Correcting IOLs: How to Predict and Prevent Failure**
 - Sunday, 11/9, 3:15-5:30 p.m., Georgia World Congress Center, Room B406

- **Optical Performance of 3D- and 4D-Add Adopized Diffractive IOLs, Full-Aperture Diffractive IOLs and Zonal Refractive IOLs in a Model Eye**
 - Monday, 11/10, 12:30-2:00 p.m., Georgia World Congress Center, Level 1, Hall B-5

- **Evaluation of Postoperative Rotational Stability of the AcrySof® Toric IOL Using a New Software**
 - Monday, 11/10, 12:30-2:00 p.m., Georgia World Congress Center, Level 1, Hall B-5

Alcon

Product Growth Drivers

Advanced Technology
IOLs

New Equipment
Platforms

New Glaucoma
Formulations

Alcon[®]

LAUREATE™ World Phaco System

LAUREATE™ Target Strategy

- Entry to mid-level phaco system
- Significant potential in emerging markets
- Enables an entry point to the Alcon portfolio of products for lower tier surgeons

LAUREATE™ Features

- Traditional ultrasound technology without QZil® torsional handpiece
- Innovative fluidic management
- Easy to use graphic user interface




Alcon

Vitreoretinal Equipment Share Development



U.S. ACCURUS[®] Installed Base Share Growth



Historical estimation based on trends,
1997-2001

Source: Internal Alcon Surveys, 1999-2000

Alcon

CONSTELLATION® Improvements over ACCURUS®

Barcode Scanner

Ultrasonics/Diathermy

Pneumatics:

- V-C Injection/Extrusion
- Pneumatic Scissors/Forceps
- ULTRAVIT™ 5000 CPM
- Auto-Gas Filling

Fluidics:

- Integrated Pressurized Infusion
– IOP Control
- Vac Control 650mmHg
- Flow Control
- Automated FIA

Embedded
PUREPOINT™ Laser

17" Display

Xenon Illumination

Articulating Tray
Arm

Auxiliary Illuminator

Primary Footswitch



Alcon

ULTRAVIT® Vitrectomy Probe Features

■ High Speed Vitrectomy Probe

- 5000 CPM and variable duty cycle control (standard 2500 CPM)
- Allows for more physician control and enables work closer to the retina



Alcon

Alcon at the AAO: Surgical Equipment

- **CONSTELLATION[®] Vision System Clinical Experiences Panel Discussion**
 - Sunday, 11/9, 9:45 a.m., Georgia World Congress Center, Alcon Booth #1300
- **CONSTELLATION[®] Vision System: Challenging Cases Panel Discussion**
 - Sunday, 11/9, 1:30 p.m., Georgia World Congress Center, Alcon Booth #1300
- **Architectural Design for CONSTELLATION[®] Vision System**
 - Monday, 11/10, 10:35 a.m., Georgia World Congress Center, Alcon Booth #1300

Alcon

Product Growth Drivers

Advanced Technology
IOLs

New Equipment
Platforms


New Glaucoma
Formulations

Alcon[®]

Growing the TRAVATAN® Family



Alcon Global Prostaglandin Market Share

TRAVATAN® Family has gained 3.8 share points following DuoTrav™ and TRAVATAN Z® launches




U.S. Rx Share of TRAVATAN Z® as a Percentage of the Total TRAVATAN® Franchise

TRAVATAN® Franchise is up 6.3 share points since TRAVATAN Z® launch



Continued Development of DuoTrav™

DuoTrav™ Market Share in EU, Australia and Canada




Source: IMS



Azopt® Gaining Global Market Share

Global TCAI Market Share Development



* Trusopt is a registered trademark of Merck.

Source: IMS

Alcon

Expanding Glaucoma Product Portfolio

AZARGA[®] Suspension


- Brinzolamide 1% / Timolol 0.5% fixed combination
- Powerful efficacy, superior comfort
- European marketing application filed in 4Q 2007
 - Positive opinion received




Alcon

Favorable Patient Response

Ocular Comfort



Patient Preference



* COSOPT is a registered trademark of Merck.

Wong JG, Pavesi RM, Stewart RH, et al. A six-week comfort study of 0.1% azargol bromide in 1% zinc borate solution in a preservative-free contact lens solution compared to a 0.1% azargol bromide in 0.2% polyborate solution in a preservative-free contact lens solution. *Journal of Ocular Pharmacology and Therapeutics* 2007; 21: 107-111.

Mason TK, Passerini SH, Williams PD, et al. A patient preference comparison of Azarga (bromolol betaxolol) and Cosopt (bimatoprost) in a preservative-free contact lens solution. *Journal of Ocular Pharmacology and Therapeutics* 2007; 21: 107-111.

Alcon

Gaining Market Share in Pharmaceuticals

<u>RX Growth</u>	Global June YTD		US September YTD		US September 2008
	Brand	Market	Brand	Market	Market
TRAVATAN® Family	16.3%	8.3%	13.4%	-0.6%	4.4%
Azopt®	7.7%	6.1%	16.1%	4.4%	5.1%
Vigamox® ¹	20.6%	7.7%	-2.3%	-4.3%	-0.7%
TobraDex®	6.8%	7.4%	-7.9%	-4.1%	0.8%
NEVANAC®	62.2%	3.4%	21.5%	9.8%	11.5%
Patanol® + Pataday™	23.1%	2.3%	-2.7%	-8.3%	-3.1%
CIPRODEX® / Cipro HC	7.4%	0.3%	7.6%	0.3%	4.3%

¹ Moxifloxacin, the active ingredient in Vigamox®, is licensed to Alcon by Bayer HealthCare AG.
CIPRODEX® is a registered trademark of Bayer AG and licensed to Alcon by Bayer HealthCare AG.

Source: Global IMS US-WK Health



Alcon at the AAO: Glaucoma

- **Optimizing Patient Care: Managing Glaucoma and Ocular Surface Disease: A Care-Based Interactive Discussion (an Ophthalmology Times Educational Symposium)**
 - **Sunday, 11/9, Marriott Marquis**
 - 6:00-6:30 a.m. Registration
 - 6:30-8:00 a.m. Symposium

- **A Study of Anecortave Acetate (7.5 and 15 mg) vs. Vehicle in Patients with Open-Angle Glaucoma**
 - **Monday, 11/10, 8:30-8:38 a.m., Georgia World Congress Center, A411**

Alcon



Alcon Investor Meeting at AAO

November 7, 2008

Alcon[®]

AcrySof® Phakic Lens Attributes

Unique design and
biocompatible material

Low haptic force and vault
dynamic response

Small incision delivery with
minimal endothelial cell loss

Effective visual correction
supported by clinical results

Refractive power range of
-6.0 to -16.5

Potential expansion to toric
and presbyopic correction



AcrySof® Phakic
(Currently not available in the U.S.)

Alcon